NASDAQ:INVA Innoviva (INVA) Stock Price, News & Analysis → Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold) (Ad) Free INVA Stock Alerts $15.53 +0.08 (+0.52%) (As of 05/7/2024 ET) Add Compare Share Share Today's Range$15.52▼$15.7250-Day Range$14.40▼$15.5452-Week Range$11.55▼$16.86Volume397,964 shsAverage Volume663,059 shsMarket Capitalization$981.96 millionP/E Ratio7.12Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Innoviva alerts: Email Address Ad Unstoppable ProsperityRSVP: Charles Payne’s Cash Flow WorkshopAre you ready to find untapped value in the stocks you already own… Without selling a single share… Then you need to know these Cash Flow Trade Strategies.Register For Free Now! About Innoviva Stock (NASDAQ:INVA)Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Read More INVA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INVA Stock News HeadlinesApril 24, 2024 | finance.yahoo.comInnoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024April 24, 2024 | businesswire.comInnoviva Specialty Therapeutics' Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024May 8, 2024 | InvestorPlace (Ad)The new financial threat that could wipe out millions…During the Internet boom, companies like Pets.com were supposed to be promising investments riding the wave of a new tech boom. But then they were gone within a blink of an eye. One of the most successful investors in history just stepped forward to say the same thing is about to happen to AI stocks.April 22, 2024 | finance.yahoo.comShould Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?March 8, 2024 | benzinga.comInsider Decision Unfolding At Innoviva: Pavel Raifeld Exercises OptionsMarch 4, 2024 | msn.comArmata enters $35M credit agreement with InnovivaFebruary 29, 2024 | finance.yahoo.comInnoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company ProgressFebruary 29, 2024 | businesswire.comInnoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company ProgressMay 8, 2024 | InvestorPlace (Ad)The new financial threat that could wipe out millions…During the Internet boom, companies like Pets.com were supposed to be promising investments riding the wave of a new tech boom. But then they were gone within a blink of an eye. One of the most successful investors in history just stepped forward to say the same thing is about to happen to AI stocks.February 28, 2024 | msn.com10 stocks you can bet on being inflation-proofFebruary 14, 2024 | finance.yahoo.comJim Simons Bolsters Position in Innoviva Inc with Recent AcquisitionFebruary 8, 2024 | morningstar.comInnoviva Inc INVAFebruary 6, 2024 | morningstar.comCosmo Pharmaceuticals NV COPNJanuary 25, 2024 | stocknews.com3 Lucrative Biotech Stock Buys for SuccessJanuary 8, 2024 | msn.comChart of the Day: Innoviva - Individual Investor FavoriteDecember 30, 2023 | finance.yahoo.comInnoviva's (NASDAQ:INVA) investors will be pleased with their 29% return over the last three yearsDecember 21, 2023 | uk.finance.yahoo.comInnoviva, Inc. (INVA) stock historical prices & data – Yahoo FinanceDecember 11, 2023 | stocknews.comAnalyzing the Bullish Opportunities of 3 Biotech StocksNovember 27, 2023 | msn.comInnoviva (INVA) Price Target Increased by 7.14% to 15.30November 18, 2023 | finance.yahoo.comInsider Sell Alert: Marianne Zhen Offloads Shares of Innoviva IncNovember 14, 2023 | finance.yahoo.comInnoviva, Inc. (NASDAQ:INVA) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?November 3, 2023 | finance.yahoo.comInnoviva Inc (INVA) Reports Q3 2023 Financial Results: Net Income Drops to $82.0 MillionNovember 1, 2023 | finance.yahoo.comPositive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated GonorrheaNovember 1, 2023 | finance.yahoo.comInnoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company ProgressOctober 18, 2023 | finance.yahoo.comCalculating The Intrinsic Value Of Innoviva, Inc. (NASDAQ:INVA)October 9, 2023 | seekingalpha.comInnoviva: A Lot Of Moving PartsSeptember 19, 2023 | finance.yahoo.comInnoviva to Participate in the Cantor Global Healthcare ConferenceSee More Headlines Receive INVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today5/07/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:INVA Previous SymbolNASDAQ:THRX CUSIP88338T10 CIK1080014 Webwww.inva.com Phone(650) 238-9600Fax650-827-8690Employees112Year Founded1996Profitability EPS (Most Recent Fiscal Year)$2.18 Trailing P/E Ratio7.16 Forward P/E RatioN/A P/E GrowthN/ANet Income$179.72 million Net Margins57.89% Pretax Margin62.52% Return on Equity30.37% Return on Assets15.70% Debt Debt-to-Equity Ratio0.66 Current Ratio9.03 Quick Ratio7.96 Sales & Book Value Annual Sales$310.46 million Price / Sales3.18 Cash Flow$3.59 per share Price / Cash Flow4.35 Book Value$10.66 per share Price / Book1.46Miscellaneous Outstanding Shares63,230,000Free Float62,342,000Market Cap$986.39 million OptionableOptionable Beta0.57 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Pavel Raifeld C.F.A. (Age 40)Chief Executive Officer Comp: $754.67kMs. Marianne Zhen CPA (Age 55)Chief Accounting Officer & Secretary Comp: $530.21kMr. Stephen Basso M.B.A. (Age 58)Chief Financial Officer Key CompetitorsVir BiotechnologyNASDAQ:VIROcular TherapeutixNASDAQ:OCULKiniksa PharmaceuticalsNASDAQ:KNSACureVacNASDAQ:CVACPhathom PharmaceuticalsNASDAQ:PHATView All CompetitorsInsiders & InstitutionsEmpowered Funds LLCBought 18,890 shares on 5/7/2024Ownership: 0.395%Swiss National BankSold 1,600 shares on 5/7/2024Ownership: 0.180%SG Americas Securities LLCBought 9,082 shares on 5/7/2024Ownership: 0.014%LSV Asset ManagementSold 156,900 shares on 5/6/2024Ownership: 0.156%Texas Permanent School Fund CorpBought 662 shares on 5/6/2024Ownership: 0.078%View All Insider TransactionsView All Institutional Transactions INVA Stock Analysis - Frequently Asked Questions How have INVA shares performed in 2024? Innoviva's stock was trading at $16.04 on January 1st, 2024. Since then, INVA shares have decreased by 3.2% and is now trading at $15.53. View the best growth stocks for 2024 here. Are investors shorting Innoviva? Innoviva saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 11,330,000 shares, a decrease of 13.0% from the March 15th total of 13,020,000 shares. Based on an average daily volume of 681,300 shares, the short-interest ratio is currently 16.6 days. Currently, 18.2% of the company's stock are short sold. View Innoviva's Short Interest. When is Innoviva's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our INVA earnings forecast. How were Innoviva's earnings last quarter? Innoviva, Inc. (NASDAQ:INVA) released its quarterly earnings data on Thursday, February, 29th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter. The biotechnology company earned $85.84 million during the quarter. Innoviva had a net margin of 57.89% and a trailing twelve-month return on equity of 30.37%. What ETFs hold Innoviva's stock? ETFs with the largest weight of Innoviva (NASDAQ:INVA) stock in their portfolio include LeaderShares Activist Leaders ETF (ACTV), Invesco Pharmaceuticals ETF (PJP), Harbor Health Care ETF (MEDI), ETC 6 Meridian Small Cap Equity ETF (SIXS), Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG), Conductor Global Equity Value ETF (CGV), SPDR S&P Pharmaceuticals ETF (XPH) and Roundhill Acquirers Deep Value ETF (DEEP). What other stocks do shareholders of Innoviva own? Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), OPKO Health (OPK) and Sorrento Therapeutics (SRNE). Who are Innoviva's major shareholders? Innoviva's stock is owned by a number of institutional and retail investors. Top institutional investors include Denali Advisors LLC (0.52%), Principal Financial Group Inc. (0.51%), Empowered Funds LLC (0.40%), Hussman Strategic Advisors Inc. (0.27%), Los Angeles Capital Management LLC (0.22%) and Swiss National Bank (0.18%). Insiders that own company stock include Alexander J Denner, George Bickerstaff, Innoviva, Inc, Marianne Zhen, Pavel Raifeld and Plc Glaxosmithkline. View institutional ownership trends. How do I buy shares of Innoviva? Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INVA) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorGold Set to EXPLODE!Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAI “wealth window” is closing June 25thParadigm Press[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsStock-Picking AI Predicts #1 Stock of 2024AltimetryElon Musk Secret Crypto Plot ExposedCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innoviva, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.